PM
TPST icon

Prosight Management’s Tempest Therapeutics TPST Stock Holding History

Prosight Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-267
Closed -$370K – 43
2019
Q3 		$370K Sell
267
-112
-30% -$181K 0.21% 34
2019
Q2 		$854K Sell
379
-1,010
-73% -$2.97M 0.43% 32
2019
Q1 		$4.06M Buy
1,389
+72
+5% +$159K 1.78% 23
2018
Q4 		$2.04M Buy
1,317
+794
+152% +$1.63M 1.05% 27
2018
Q3 		$1.12M Buy
+523
New +$1.26M 0.62% 30

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management's TPST Position: Q4 2019 in Review

Prosight Management sold out of Tempest Therapeutics (TPST) in Q4 2019, closing a stake of 267 shares — an estimated $370K sold.

Prosight Management first reported a position in TPST in Q3 2018 and held it in 5 quarters. The position peaked at $4.06M in Q1 2019. 50 funds tracked by Wall St. Rank hold TPST as of Q4 2019.

  • Prosight Management reported no remaining Tempest Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Prosight Management sold 267 Tempest Therapeutics shares in Q4 2019, an estimated $370K.
  • Prosight Management first reported a position in Tempest Therapeutics in Q3 2018 and held it in 5 quarters.
  • Prosight Management's Tempest Therapeutics position peaked at $4.06M in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2019.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.